Uterine LeiomyosarcomaPhase 2NCT02378142
Pazopanib for Treating Uterine Leiomyosarcoma
A Phase 2 study testing Pazopanib in people with Uterine Leiomyosarcoma, run by Gynecologic Oncology Group.
Trial summary
The purpose of this study is to test any good and bad effects of the study drug pazopanib. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Uterine Leiomyosarcoma
- What is being tested?
- Pazopanib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Mar 2015to Jan 2018
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Recurrent or persistent leiomyosarcoma of the uterus.
- measurable disease.
- Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST version 1.1 (Section 8.1).
- Patients must not be eligible for a higher priority GOG protocol, if one exists. In general, this would refer to any active GOG Phase III protocol.
- GOG Performance Status of 0, 1, or 2.
- Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated UTI).
Show all 30Show fewer
- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Hormonal therapy will not count as a prior regimen (either cytotoxic or non-cytotoxic).
- Any other prior therapy directed at the malignant tumor, including chemotherapy and immunologic agents, must be discontinued at least three weeks prior to registration.
- Any prior radiation therapy must be completed at least 2 weeks prior to registration.
- At least 4 weeks must have elapsed since the patient underwent any major surgery (for example, hysterectomy, resection of a metastatic nodule); placement of a central venous catheter is considered minor, not major and thus time from a minor procedure until treatment on study may be shorter than 4 weeks.
- Patients must have had at least one prior chemotherapeutic regimen for management of leiomyosarcoma.
- Patients may have had one additional chemotherapeutic regimen for management of leiomyosarcoma, for a total of two prior lines of therapy.
- Patients must have NOT received any non-cytotoxic (biologic or targeted) agents as part of their primary treatment or for management of recurrent or persistent disease. (Patients who were previously treated on GOG 0250, a randomized trial of gemcitabine-docetaxel plus bevacizumab or placebo, are eligible, provided that the patient is known to have been treated on the placebo-containing arm and did not receive prior bevacizumab)
- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl (1.5 x 109/L). Platelets greater than or equal to 100,000/mcl (100 x 109/L). Hemoglobin greater than or equal to 9 g/dL. Patients may not have had blood transfusion or platelet transfusion within 7 days of screening assessment.
- Creatinine less than or equal to 1.5 mg/dL (133 umol/L) or, if >1.5 mg/dl, then calculated creatinine clearance must be greater than or equal to 30 mL/min.
- Hepatic function:
- Bilirubin less than or equal to 1.5 x ULN (subjects with Gilbert's syndrome and elevations of indirect bilirubin only are eligible).
- AST and ALT less than or equal to 2.5 x ULN and alkaline phosphatase less than or equal to 2.5 x ULN.
- Subjects who have BOTH bilirubin greater than ULN and AST/ALT greater than ULN are not eligible. (Specifically, if bilirubin is greater than 1 x ULN but less than or equal to 1.5 x ULN, THEN the AST and ALT must be less than or equal to ULN for patient to be eligible. If AST and /or ALT are greater than 1 x ULN but less than or equal to 2.5 x ULN, THEN the bilirubin must be less than or equal to ULN for patient to be eligible.)
- Urine Protein/ Creatinine Ratio (UPCR) must be less than 1 (or urinary protein less than 1 g/24 hours). -Blood coagulation parameters: PT such that international normalized ratio (INR) is less than or equal to 1.2 x ULN (Patients on anticoagulant therapy are eligible if their INR is stable, and in-range INR, usually between 2 and 3) and a PTT less than or equal to 1.2 x ULN.
- Patients must have signed an approved informed consent and authorization permitting release of personal health information.
- Patients who have met the pre-entry requirements specified in section 7.0.
- Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception.
- Patients must be 18 years or older.
- Patients must be capable of taking and absorbing oral medications.
- Any concomitant medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes should be discontinued or replaced with drugs that do not carry these risks, if possible. Patients who must take medication with a risk of possible risk of Torsades de Pointes should be watched carefully for symptoms of QTc prolongation, such as syncope. See Appendix III for a list of concomitant medications associated with QTc and Torsades de Pointes.
- Patients with personal or family history of congenital long QTc syndrome are NOT eligible.
- CYP3A4 Inhibitors: Strong inhibitors of CYP3A4 are prohibited. Grapefruit juice is also an inhibitor of CYP450 and should not be taken with pazopanib.
- CYP3A4 Inducers: Strong inducers of CYP3A4 are prohibited.
- CYP Substrates: Concomitant use of agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not recommended.
Who cannot join
- Prior therapy with pazopanib.
- Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted in Sections 3.23 and 3.24, are excluded if there is any evidence of other malignancy being present within the last three years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
- Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of uterine leiomyosarcoma within the last three years are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of uterine leiomyosarcoma within the last three years are excluded. Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease.
- Patient has been treated with an investigational agent or device within 30 days of entering the study.
- Patient is known to have history of active Hepatitis B or C.
Show all 32Show fewer
- Patients with clinically significant cardiovascular disease. This includes:
- Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility. (Note: initiation of antihypertensive medications is permitted prior to study entry. At least 24 hours must have elapsed between antihypertensive medication initiation and BP measurement. At that time the BP should be measured 3 times, approximately 2 minutes apart, the 3 values should be averaged. This average or mean BP must be less than 140/90 mmHg.
- Myocardial infarction or unstable angina or cardiac angioplasty or cardiac stenting or coronary artery bypass graft surgery or symptomatic peripheral vascular disease within 6 months of the first date of pazopanib therapy.
- New York Heart Association (NYHA) Class II or greater congestive heart failure (Appendix II).
- Women who have received prior anthracycline (e.g., doxorubicin and/or liposomal doxorubicin) and who have an ejection fraction less than the institutional lower limit of normal will be excluded from the study. Patients with a prior life time exposure to doxorubicin (or liposomal doxorubicin) of greater than 300 mg/m2 are NOT eligible.
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of pazopanib therapy.
- Women with a baseline QTc >480 milliseconds.
- History of cerebrovascular accident, including transient ischemic attack, or pulmonary embolism, within the past 6 months. (Note: subjects with recent DVT only (no PE) who have been treated with therapeutic anticoagulation for at least six weeks are eligible).
- A patient with arterial thrombosis within 6 months prior to enrollment.
- Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases.
- Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
- Serious, non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to the first date of pazopanib therapy. Patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib.
- HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pazopanib. In addition, these subjects are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
- Patients who are pregnant or nursing. Patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
- Patients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including but not limited to:
- active peptic ulcer disease
- known gastrointestinal intraluminal metastatic lesions with risk of bleeding (gastrointestinal serosa metastatic lesion are permitted)
- inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions with increased risk of perforation
- history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days prior to beginning study treatment
- History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of pazopanib.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
- Major surgery or trauma within 28 days prior to first dose of pazopanib. (procedures such as catheter placement or central venous access device placement are not considered major surgery)
- Patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage. (Note, the presence of tumor that is touching but not infiltrating is acceptable; large protruding endobronchial lesion in the main or lobar bronchi are excluded; lesion extensively infiltrating the main or lobar bronchi are excluded)
- Patients who are unwilling or unable to discontinue use of prohibited medications for at least 14 days prior to the first dose of study drug and for the duration of the study (see APPENDIX III regarding concomitant medications for the section titled "prohibited medications").
About this study
Official title: A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
The purpose of this study is to test any good and bad effects of the study drug pazopanib.
- Conditions
- Uterine Leiomyosarcoma
- Being tested
- Pazopanib
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PazopanibDrug
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Pazopanib 800mg oral daily Receives: Drug: Pazopanib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Event free survival
To estimate the proportion of patients with persistent or recurrent uterine leiomyosarcoma, who survive event-free for at least 6 months (EFS > 6 months; events associated with the endpoint are death, disease progression, or beginning a subsequent therapy) and the proportion of patients who have objective tumor response (complete or partial), treated with pazopanib.
Measured: 6 months
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
To determine the nature and degree of toxicity of pazopanib in this cohort of patients
Measured: Every 4 weeks
Secondary outcomes (3)
Progression-free survival
To estimate progression-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus
Measured: Every 3 months from time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years
Event-free survival
To estimate event-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus
Measured: Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years
Overall survival
To estimate overall survival in patients with recurrent or persistent leiomyosarcoma of the uterus
Measured: Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2015 (estimated)
- Study startMar 2015
- Primary completionJan 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine LeiomyosarcomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gynecologic Oncology Group
- Sponsor type
- Research network
- Collaborators
- GlaxoSmithKline
- Responsible party
- Sponsor
- Investigators
- Martee Hensley, MD, Study chair, MSKCC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02378142
- Sponsor's protocol ID
- GOG-3006
- Status last verified
- Nov 2015
- First submitted
- 17 Feb 2015
- Last updated
- 18 Nov 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
- ClinicalTrials.gov ID
- NCT02378142
- Acronym / sponsor ID
- GOG-3006
- Conditions
- Uterine Leiomyosarcoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Gynecologic Oncology GroupResearch network
- Collaborators
- GlaxoSmithKline
- Study start
- Mar 2015
- Primary completion
- Jan 2018 (estimated)
- First posted
- 4 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test any good and bad effects of the study drug pazopanib.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Drug: PazopanibPazopanib 800mg oral daily |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (30 listed)
- Recurrent or persistent leiomyosarcoma of the uterus.
- measurable disease.
- Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST version 1.1 (Section 8.1).
- Patients must not be eligible for a higher priority GOG protocol, if one exists. In general, this would refer to any active GOG Phase III protocol.
- GOG Performance Status of 0, 1, or 2.
Key exclusion criteria (32 listed)
- Prior therapy with pazopanib.
- Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted in Sections 3.23 and 3.24, are excluded if there is any evidence of other malignancy being present within the last three years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
- Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of uterine leiomyosarcoma within the last three years are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of uterine leiomyosarcoma within the last three years are excluded. Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease.
- Patient has been treated with an investigational agent or device within 30 days of entering the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pazopanib | Drug | Arm 1 |
Primary outcome
Event free survival
Time frame: 6 months
To estimate the proportion of patients with persistent or recurrent uterine leiomyosarcoma, who survive event-free for at least 6 months (EFS > 6 months; events associated with the endpoint are death, disease progression, or beginning a subsequent therapy) and the proportion of patients who have objective tumor response (complete or partial), treated with pazopanib.
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: Every 4 weeks
To determine the nature and degree of toxicity of pazopanib in this cohort of patients
3 secondary outcomes
Progression-free survival
Time frame: Every 3 months from time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years
Event-free survival
Time frame: Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years
Overall survival
Time frame: Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2015.
Related trials for Uterine Leiomyosarcoma
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 2
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
Uterine Leiomyosarcoma
Active, not recruitingPhase 2/3
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma
RecruitingPhase 2
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Leiomyosarcoma Uterus
Active, not recruitingPhase 2
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martee Hensley, MD study chair
MSKCC
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pazopanib in people with Uterine Leiomyosarcoma, run by Gynecologic Oncology Group.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 30 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event free survival (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2015.